computer generated randomisation list (Serono)
86
Structured Review
Serono
computer generated randomisation list
Computer Generated Randomisation List, supplied by Serono, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/computer-generated+randomisation+list/computer+generated+list+randomisation/pmc10687854-2344-10-16
Average 86 stars, based on 1 article reviews
Computer Generated Randomisation List, supplied by Serono, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/computer-generated+randomisation+list/computer+generated+list+randomisation/pmc10687854-2344-10-16
Average 86 stars, based on 1 article reviews
computer generated randomisation list - by Bioz Stars,
2026-11
86/100 stars
Images
Related Articles
Sequencing:Article Title: Immunomodulators and immunosuppressants for multiple sclerosis: a network meta‐analysis Article Snippet: .. Random sequence generation (selection bias) , Low risk , " Article Title: Interferon beta for secondary progressive multiple sclerosis Article Snippet: .. Random sequence generation (selection bias) , Low risk , Article Title: Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis Article Snippet: Relapses were assessed also as adverse events SPECTRIMS 2001 Methods RCT Participants Age: 18-55 years; clinical definite SPMS; progression ≥ 1 EDSS over the previous 2 years, with or without superimposed relapses before randomisation; EDSS 3.0-6.5; mean disease duration 14 years Interventions IFNß -1a (Rebif ) 22 μg subcutaneous three times/week for 3 years (n. 209) IFNß -1a (Rebif ) 44 μg subcutaneous three times/week for 3 years (n. 204) Placebo (unspecified) for 3 years (n. 205) Outcomes Progression at 24 and 36 months Notes Funding: Serono International, Geneva, Switzerland .. Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk Selection:Article Title: Immunomodulators and immunosuppressants for multiple sclerosis: a network meta‐analysis Article Snippet: .. Random sequence generation (selection bias) , Low risk , " Article Title: Interferon beta for secondary progressive multiple sclerosis Article Snippet: .. Random sequence generation (selection bias) , Low risk , Article Title: Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis Article Snippet: Relapses were assessed also as adverse events SPECTRIMS 2001 Methods RCT Participants Age: 18-55 years; clinical definite SPMS; progression ≥ 1 EDSS over the previous 2 years, with or without superimposed relapses before randomisation; EDSS 3.0-6.5; mean disease duration 14 years Interventions IFNß -1a (Rebif ) 22 μg subcutaneous three times/week for 3 years (n. 209) IFNß -1a (Rebif ) 44 μg subcutaneous three times/week for 3 years (n. 204) Placebo (unspecified) for 3 years (n. 205) Outcomes Progression at 24 and 36 months Notes Funding: Serono International, Geneva, Switzerland .. Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk Generated:Article Title: Immunomodulators and immunosuppressants for multiple sclerosis: a network meta‐analysis Article Snippet: .. Random sequence generation (selection bias) , Low risk , " Article Title: Interferon beta for secondary progressive multiple sclerosis Article Snippet: .. Random sequence generation (selection bias) , Low risk , Article Title: Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis Article Snippet: Relapses were assessed also as adverse events SPECTRIMS 2001 Methods RCT Participants Age: 18-55 years; clinical definite SPMS; progression ≥ 1 EDSS over the previous 2 years, with or without superimposed relapses before randomisation; EDSS 3.0-6.5; mean disease duration 14 years Interventions IFNß -1a (Rebif ) 22 μg subcutaneous three times/week for 3 years (n. 209) IFNß -1a (Rebif ) 44 μg subcutaneous three times/week for 3 years (n. 204) Placebo (unspecified) for 3 years (n. 205) Outcomes Progression at 24 and 36 months Notes Funding: Serono International, Geneva, Switzerland .. Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk Blocking Assay:Article Title: Immunomodulators and immunosuppressants for multiple sclerosis: a network meta‐analysis Article Snippet: .. Random sequence generation (selection bias) , Low risk , " Article Title: Interferon beta for secondary progressive multiple sclerosis Article Snippet: .. Random sequence generation (selection bias) , Low risk , Article Title: Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis Article Snippet: Relapses were assessed also as adverse events SPECTRIMS 2001 Methods RCT Participants Age: 18-55 years; clinical definite SPMS; progression ≥ 1 EDSS over the previous 2 years, with or without superimposed relapses before randomisation; EDSS 3.0-6.5; mean disease duration 14 years Interventions IFNß -1a (Rebif ) 22 μg subcutaneous three times/week for 3 years (n. 209) IFNß -1a (Rebif ) 44 μg subcutaneous three times/week for 3 years (n. 204) Placebo (unspecified) for 3 years (n. 205) Outcomes Progression at 24 and 36 months Notes Funding: Serono International, Geneva, Switzerland .. Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk |